logo
Further batches of spinach recalled over listeria

Further batches of spinach recalled over listeria

RTÉ News​a day ago
Batches of two further spinach products sold in Irish supermarkets have been recalled due to the detection of listeria monocytogenes.
The Food Safety Authority of Ireland (FSAI) has issued alerts for two further products, one by McCormack Family Farms and another by Fresh Choice.
The following batches of 500g McCormack Family Farms Irish Spinach Leaves have been recalled: L199, L200, L202, L203, L204 and L205.
While Fresh Choice Market Spinach Leaves 100g with the following use-by dates have also been recalled: 25/07/2025, 26/07/2025, 27/07/2025, 28/07/2025, 29/07/2025, 30/07/2025 and 31/07/2025.
The FSAI has requested that retailers remove the implicated products from sale, and display recall notices at point-of-sale.
Wholesalers and distributors are being asked to contact their affected customers and recall the affected products and put a recall notice in place.
Caterers who may be in possession of the impacted products have been asked not to use them, while consumers are advised not to eat them.
The FSAI has said there is currently "no evidence that this food recall is linked with the listeriosis outbreak related to ready-to-heat meals that is currently under investigation".
Over 200 ready-made meals produced by Ballymaguire Foods were called back early last week.
The authority said that one person with a confirmed case of listeria died, while nine other cases were identified as of Tuesday last week.
The FSAI's latest update follows a recall yesterday of seven spinach and mixed leaves products following detection of harmful bacteria Listeria monocytogenes.
The FSAI said that symptoms of listeria can include mild flu-like symptoms such as gastrointestinal symptoms such as nausea, vomiting and diarrhoea.
Symptoms can be more severe in rare cases, it added.
"Some people are more vulnerable to listeria monocytogenes infections, including pregnant women, babies, and people with weakened immune systems, including the elderly.
"The incubation period (time between initial infection and first symptoms appearing) is on average three weeks but can range between 3 and 70 days," said the FSAI.
The FSAI said today that to date, there are no cases of listeriosis associated with the spinach and mixed leaves products that were subject of yesterday's recall.
How inspections are carried out
The FSAI and official agencies carry out inspections of food production facilities and review all the control measures in place.
This includes examining the testing regimes for listeria at the factory and also taking official control samples of food and equipment.
These official control samples are tested for listeria monocytogenes in accredited laboratories run by the State.
Where listeria monocytogenes is found in any official control samples, enforcement action is taken to minimise or eliminate the risk to consumers.
"Precautionary recalls of food due to Listeria monocytogenes can be found by either the food business itself or the authorities and happen from time to time, reflecting the high level of awareness, control and testing that takes place in factory settings," the FSAI said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MSD won't close Irish sites as part of $3bn cutbacks
MSD won't close Irish sites as part of $3bn cutbacks

Irish Examiner

time10 minutes ago

  • Irish Examiner

MSD won't close Irish sites as part of $3bn cutbacks

Pharmaceutical giant MSD is slashing $3bn (€2.59bn) from its annual spending as part of global job cut but said it will not be closing any of its Irish sites. MSD yesterday announced a global cost-cutting exercise as it prepares for generic competition to its Irish-manufactured cancer drug Keytruda, the world's best-selling medicine, which is predominantly made in Ireland. The company will cut administrative, sales and research jobs, with increased focus on the US market. It has not said where the roles will be lost or if any Irish workers will be among those affected. However, a spokesperson told the Irish Examiner: "The restructuring announced today does not include site closures in Ireland." MSD employs more than 3,000 people at eight locations in Ireland. These include MSD Brinny in Co Cork specialising in development and manufacture of innovative novel vaccines and testing of immuno-oncology medicines; three facilities in Dublin (MSD Biotech, MSD Blackrock, and MSD Red Oak North); MSD Carlow; MSD Dunboyne in Co Meath; MSD Ballydine in Co Tipperary, the company's first Irish site; and MSD Dundalk, the former WuXi Vaccines sites acquired in January. The cost cuts will include $1.7bn (€1.47bn) in annual savings from the elimination of certain administrative, sales and R&D positions, MSD said. The company expects the restructuring to be completed by the end of 2027, the year before Keytruda's key patents expire and the drug faces US government price cuts. The company said it plans to reinvest the savings into developing new drugs and launching new products. EU-branded medicines will face 15% import tariffs under the new transatlantic trade deal agreed between the European bloc and the US at the weekend. Like many other pharmaceutical firms based in Ireland, MSD had stockpiled doses of Keytruda manufactured in Ireland, to protect itself from tariffs imposed in 2025. MSD previously disclosed plans to invest more than $9bn (€7.78bn) in US manufacturing over the next four years, part of an effort to make more of its medicines in the US. The company reiterated that it expects to spend $200m (€172m) on tariffs in 2025, a number that reflects levies already in place and doesn't account for future tariffs on pharmaceuticals.

US patients will pay cost of Donald Trump's 15 per cent tariffs on EU's pharma industry, Irish boss warns
US patients will pay cost of Donald Trump's 15 per cent tariffs on EU's pharma industry, Irish boss warns

The Irish Sun

timean hour ago

  • The Irish Sun

US patients will pay cost of Donald Trump's 15 per cent tariffs on EU's pharma industry, Irish boss warns

AMERICAN patients will pay the cost of Donald Trump's 15 per cent tariffs on Europe's pharmaceutical industry, an Irish pharma company boss has warned. The Advertisement 2 CEO of Nutriband Gareth Sheridan fears the impact of the tariffs There Tanaiste Gareth Sheridan is CEO of Nutriband – a pharma company that specialises in patch technologies to enable safer use of pain medications and reduces the risk of addiction. The company is in a unique position in that they are based in the US and so will not face the 15 per cent tariffs. Advertisement Read more in News However, He told the Irish Sun: 'We won't be hugely impacted by the tariffs directly but we will be because we will be caught up in the industry impact. 'As a company that likes to describe ourselves as patient focused, we're very concerned at the effect that this will have on patients at the end of the day. 'Primarily that is where the fallout is going to be. To give you an example, 60 per cent of patients battling cancer in America today struggle with the cost of care as it is – and that's without a 15 per cent hike. Advertisement Most read in Irish News 'If you can imagine a 15 per cent hike in the cost of any sort of chemotherapies that is now being imported at a US level – that is very problematic. 'That's about two million people that are today barely making ends meet because of the cost of chemotherapy and you're going to have a 15 per cent price hike most likely unless the pharmaceutical companies absorb that cost.' US and EU agree landmark trade deal after months of talks, Donald Trump says The Irish pharma company boss believes that patients are being left behind in the discussion on tariffs as the majority of the discussion has been about the impact on jobs and the economy. He said: 'When it comes to negotiations and these discussions, ultimately people aren't statistics and patients need to be kept top of the narrative. Advertisement 'When we were talking bigger numbers and job losses and how its going to effect the economy and all those things – that's terrible. 'But ultimately when people are going to die - and they will die because they can't afford to live - I think that is a very dangerous precedent to set globally.' RESPONSE TEAM SET UP It comes as Business Minister Peter Burke established a Tariff Response Team to support Irish exporters who will be hit by the new 15 per cent tariffs. The trade team will give advice to businesses and manage new grants and funds that are being made available to assist Irish companies. Advertisement These include new market discover funds of up to €150,000 to help companies expand to new countries and €35,000 research grants to help firms mitigate the impact of the trade shake up. 2 The US clarified that pharma exports from the EU will be included in the tariffs Credit: Christopher Furlong/Pool via REUTERS

'Help us save little Éabha.' Family make appeal for baby's overseas treatment
'Help us save little Éabha.' Family make appeal for baby's overseas treatment

Irish Daily Mirror

time3 hours ago

  • Irish Daily Mirror

'Help us save little Éabha.' Family make appeal for baby's overseas treatment

An Irish family have made an urgent appeal for help as their beloved one-year-old daughter prepares to travel for life-saving treatment overseas - just weeks after they tragically lost their adored three-year-old daughter to the same rare condition. Éabha Duggan, born on June 24, 2024, has been diagnosed with a rare and serious genetic condition that requires a bone marrow transplant – a treatment not currently available in Ireland. Her only option is to travel to Prinses Máxima Centrum in Utrecht, a world-leading specialist children's hospital in the Netherlands. The Duggan family of Mayo and Galway are now making an urgent public appeal for financial support as their one-year-old daughter prepares for the life-saving bone marrow transplant in the coming weeks. For parents Tommy (from Bekan, Claremorris, Mayo) and Martina Duggan (originally from Eyrecourt, Galway), this is an unimaginable second journey down a path of profound sorrow. Their eldest daughter, Saoirse, bravely battled leukaemia after being diagnosed in late 2023. She underwent a bone marrow transplant in February 2024, but tragically, the disease returned months later, and she passed away peacefully on June 15, 2025, surrounded by love. "To face such loss and now fight for another child's life is more than any family should have to bear," says Éabha's aunt, who has launched a fundraising campaign with the family's permission. "While the medical costs for Éabha's transplant are covered by the HSE, the overwhelming financial burden of travel, and related living expenses in the Netherlands falls entirely on the family." Time is critical for Éabha. The "Together for Éabha" GoFundMe campaign has been established in response to the many friends, neighbours, and kind-hearted people who've asked how they can help. This initiative aims to alleviate the significant financial strain, allowing Tommy and Martina to focus solely on their daughter's treatment and recovery. All donations will go directly to the Duggan family to support Éabha's medical care and associated costs. To donate to the fundraiser, head here. Subscribe to our newsletter for the latest news from the Irish Mirror direct to your inbox: Sign up here. The Irish Mirror's Crime Writers Michael O'Toole and Paul Healy are writing a new weekly newsletter called Crime Ireland. Click here to sign up and get it delivered to your inbox every week

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store